Thursday, June 21, 2012

Targeting Tumor Microenvironment, Boston: Pre-meeting notes 1

"Targeting the Tumor Microenvironment" meeting will take place in Boston in October and will be looking at how to achieve tumor delivery, tackle drug resistance and improve clinical efficacy.

The interest in TME research has reached a pivotal moment. With huge investment from drug developers complimenting groundbreaking academic research, the industry is set to explode.

The program for Targeting the Tumor Microenvironment is now finalized and will focus on translating the science behind TME research into commercial drug development,

With 19 expert speakers including leading cancer researchers
Michael Lisanti, Richard Pestell and Robert Weinberg as well as companies such as Johnson & Johnson, Genentech, Pfizer and Bristol-Myers Squibb; this meeting will be the first of it’s kind.

Designed in collaboration with Professor Michael Lisanti, founder of “The Autophagic Tumor Stroma Model of Cancer Metabolism”, Targeting the Tumor Microenvironment will outline how knowledge of the TME can decrease clinical attrition rates and improve the commercial outlook for cancer therapeutics.

What’s on the agenda?
  • Explore enzymatic remodeling of the stroma to exploit tumor-specific biophysical properties for therapy
  • Overcome resistance to anti-angiogenesis agents and improve the efficacy of front-line chemotherapeutics by targeting the tumor microenvironment
  • Develop effective oncology biomarkers to successfully predict disease progression and explore the predictive utility of biomarkers for anti-angiogenesis agents
  • Target the tumor microenvironment with hypoxia activated prodrugs in combination with other therapeutics to achieve a more effective treatment strategy
  • Overcome the challenges of preclinical model development for the TME and discover the best models to optimize reliability of preclinical results
Speakers include:
  • Jonathan Yingling, Vice President, Translational Science & Technology, Eli Lilly
  • Raffaele Baffa, Senior Director, Translational & Experimental Medicine, Sanofi-Aventis
  • Giovanni Melillo, Medical Director, Discovery Medicine, Bristol-Myers Squibb
  • Richard Schlegel, Professor, Georgetown University Medical School
  • Aristotelis Tsirigos, Research Scientist, IBM
  • H. Michael Shepard, Vice President & Chief Scientific Officer, Halozyme Therapeutics
  • Mark Matteucci, Senior Vice President, Discovery, Threshold Pharmaceuticals

For more information, please:      

Call: +1 212 537 5898 
*This post is brought to you by arrangement with the meeting organiser Hanson Wade, London
Click here for other posts related to this meeting.

No comments:

Post a Comment